Status:
COMPLETED
An Observational Study, Called DEAR, to Learn More About Treatment With Darolutamide, Enzalutamide and Apalutamide in Men With Non-metastatic Castration-resistant Prostate Cancer in Real World Settings
Lead Sponsor:
Bayer
Conditions:
Non-metastatic Castration-resistant Prostate Cancer
Eligibility:
MALE
18+ years
Brief Summary
This is an observational study in which patient data from the past on men with non-metastatic castration-resistant prostate cancer are studied. In observational studies, only observations are made wit...
Eligibility Criteria
Inclusion
- Men diagnosed with prostate cancer
- Diagnosis of castration-resistant prostate cancer (CRPC) prior to or during the patient identification period
- Treatment with daro, enza, or apa initiated for the first time during the patient identification period for nmCRPC
- Age ≥ 18 years at index date
- At least 6 months of electronic medical records (EMR) activity after the index date unless the patient died earlier than 6 months
Exclusion
- Evidence of metastatic disease before or 30 days after index date.
- Prior history (within five years before index date) of other primary cancers, except for non-melanoma skin cancer
- Patients with multiple SGARIs recorded at index date
- Use of a NAH agent (daro, enza, apa or abiraterone acetate) prior to the index date
- Evidence of inclusion in clinical trials during the study period.
Key Trial Info
Start Date :
April 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 30 2023
Estimated Enrollment :
870 Patients enrolled
Trial Details
Trial ID
NCT05362149
Start Date
April 4 2022
End Date
June 30 2023
Last Update
March 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bayer
Whippany, New Jersey, United States, 07981